Clinical Trial

A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of SC0062 capsule compared to placebo in patients with IgA nephropathy in the presence of proteinuria. The participants must have a high risk of disease progression, despite of stable use of the maximum tolerated labelled or optimized dose of RAASi and/or SGLT2i for at least 12 weeks prior to randomization.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-05.
Trial Details
NCT Number NCT06819826
Lead Sponsor Biocity Biopharmaceutics Co., Ltd.
Conditions IgA Nephropathy (IgAN)
Enrollment 360 participants
Start Date 2025-02-14
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-17